|Description||Palmitoylethanolamide is an endogenous cannabinoid found in brain, liver, and other mammalian tissues. It is a weak ligand of the cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptors, and a selective GPR55 agonist (EC50 values are 4, 19 800 and > 30 000 nM at GPR55, CB2 and CB1 receptors respectively).
Nutritional supplement in health care products.
|Synonyms||N-(2-Hydroxyethyl)hexadecanamide; Palmidrol; PEA|
|Storage||Store in a cool and dry place (or refer to the Certificate of Analysis).|
|Application||Ingredient of health care products.|
AM4113 has been found to be a CB1 antagonist and could be used in studies of some neuronal dendritic abnormalities diseases.
PF 514273 is a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of obesity. The Ki for binding to CB1 and CB2 receptors is 1 nM ...
UCM 707 is a potent endocannabinoid transport inhibitor (IC50 = 0.8 and 30 μM for inhibition of the anandamide transporter and FAAH, respectively). UCM 707 pote...
NIDA-41020 is a CB1 cannabinoid receptor antagonist with Ki value of 4.1 nM.
Palmitoylethanolamide is an endogenous cannabinoid found in brain, liver, and other mammalian tissues. It is a weak ligand of the cannabinoid 1 (CB1) and cannab...
L-768242, an indole derivative, has been found to be a CB2 receptor agonist and was once studied to exhibit anti-nociceptive and antihyperalgesic activities in ...
Otenabant, also known as CP-945,598, is a drug which acts as a potent and highly selective CB1 antagonist. It was developed by Pfizer for the treatment of obesi...
Rimonabant is a selective antagonist of CB1 with IC50 of 13.6 nM and EC50 of 17.3 nM in hCB1 transfected HEK 293 membrane.